In this article, we will list the 5 Overlooked Growth Stocks to Buy Now. Please visit 10 Overlooked Growth Stocks to Buy Now to see the extended list and the methodology behind it.

5. Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the overlooked growth stocks to buy now. On March 28, Arcutis Biotherapeutics presented new Phase 2 data from its INTEGUMENT-INFANT trial at the 2026 American Academy of Dermatology Annual Meeting. The study evaluated ZORYVE (roflumilast) cream 0.05% in infants aged 3 to 24 months with mild to moderate atopic dermatitis. Results showed the once-daily, non-steroidal treatment was well tolerated and improved skin clearance, with ~half of the participants achieving Clear or Almost Clear status after 4 weeks of treatment.

A standout finding from the study was the rapid relief of itch, a primary distress factor for infants and their families. Caregivers reported visible improvements in scratching and itching in as little as 10 minutes for ~47% of the infants. Furthermore, the cream showed high efficacy in treating sensitive areas like the scalp, with 67.5% of affected infants reaching Clear or Almost Clear scalp ratings by the end of the month-long study.

The safety profile remained consistent with previous pediatric trials, showing minimal application site irritation and no serious adverse events. Based on these outcomes, Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) plans to submit a supplemental NDA to the FDA in Q2 2026. If approved, this would expand the ZORYVE portfolio (which already includes formulations for plaque psoriasis and seborrheic dermatitis) to provide a targeted, long-term topical option for the most vulnerable pediatric populations.

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) develops and commercializes treatments for dermatological diseases. Its lead product is a topical roflumilast cream for plaque psoriasis & atopic dermatitis, called ZORYVE.

4. ​Telix Pharmaceuticals Limited (NASDAQ:TLX)

​Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the overlooked growth stocks to buy now. On April 14, Telix Pharmaceuticals announced the dosing of the first patient in its pivotal Phase 3 IPAX-BrIGHT trial. This marks a historic milestone as the first radiopharmaceutical therapy to reach Phase 3 development for recurrent glioblastoma, a highly aggressive and difficult-to-treat form of brain cancer. The trial is evaluating the safety and efficacy of TLX101-Tx (¹³¹I-iodofalan) in combination with the chemotherapy drug lomustine, compared to chemotherapy alone.

The treatment uses a novel small-molecule approach to target the L-type amino acid transporter 1 (LAT1). Because LAT1 is overexpressed in glioblastoma cells, the radiopharmaceutical can successfully cross the blood-brain barrier to deliver targeted radiation directly to the tumor site. This mechanism is particularly significant given that only two drugs have been FDA-approved for glioblastoma in the last 25 years, and there is currently no established standard of care for patients once the disease recurs.

The Phase 3 study builds on encouraging data from earlier trials, such as IPAX-1, which showed a median overall survival of 13 months from the start of treatment. In the IPAX-BrIGHT trial, Telix’s companion PET imaging agent, TLX101-Px, will be used to select eligible patients and monitor their metabolic response to the therapy. With regulatory approvals already secured in Australia and several European nations, ​Telix Pharmaceuticals Limited (NASDAQ:TLX) aims for this registration-enabling study to establish a first-in-class therapy for a patient population with very limited options.

​Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biopharma company that specializes in therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. The company develops clinical and commercial-stage products to address unmet medical needs in oncology and rare diseases.

3. GitLab Inc. (NASDAQ:GTLB)

GitLab Inc. (NASDAQ:GTLB) is one of the overlooked growth stocks to buy now. On April 16, GitLab released GitLab 18.11, introducing advanced agentic AI capabilities designed to accelerate the entire DevSecOps lifecycle. A key highlight is the general availability of Agentic SAST Vulnerability Resolution, which automatically generates and proposes code fixes for security vulnerabilities. By analyzing scan results and opening ready-to-merge requests, the tool aims to help developers resolve issues before they reach production, addressing the AI Paradox where fast code generation often outpaces security remediation.

The update also features two new specialized agents within the GitLab Duo Agent Platform to streamline operations and analytics. The CI Expert Agent (in beta) can automatically configure build-and-test pipelines by identifying a repository’s language and framework, eliminating the need for manual YAML writing. Additionally, the Data Analyst Agent is now generally available, allowing users to ask natural-language questions about software lifecycle data (such as deployment frequency or pipeline health) and receive immediate visual insights.

To support enterprise-wide adoption, GitLab Inc. (NASDAQ:GTLB) implemented new usage and spending controls for GitLab Credits. Organizations can now set subscription-level and per-user spending caps to ensure predictable costs while scaling AI features. These controls, combined with the new agentic capabilities, reinforce GitLab’s strategy of providing an intelligent orchestration platform that enhances productivity and reduces security risks across the software engineering process.

GitLab Inc. (NASDAQ:GTLB) develops and operates a comprehensive DevSecOps platform delivered as a single application, allowing teams to plan, build, secure, and deploy software faster. The company provides an all-in-one solution that integrates source code management, continuous integration/continuous deployment pipelines, and security monitoring.

2. Travere Therapeutics Inc. (NASDAQ:TVTX)

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the overlooked growth stocks to buy now. On April 13, Travere Therapeutics announced that the US FDA granted full approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis/FSGS. This milestone makes FILSPARI the first and only FDA-approved medication for FSGS, a rare kidney disease that causes scarring in the filtering units of the kidney. The approval specifically covers adult and pediatric patients aged 8 years and older who do not have nephrotic syndrome.

The approval is supported by data from the Phase 3 DUPLEX Study, the largest interventional trial ever conducted in FSGS. In patients without nephrotic syndrome, those treated with FILSPARI achieved a statistically significant 48% reduction in proteinuria (excess protein in the urine) after 108 weeks, compared to a 27% reduction in those taking the active comparator, irbesartan. Additionally, FILSPARI showed a benefit in preserving the estimated glomerular filtration rate/eGFR, a key measure of kidney function, while maintaining a safety profile comparable to existing standard-of-care treatments.

FILSPARI uses a dual mechanism of action, targeting both endothelin A and angiotensin II receptors. By blocking these two pathways, the drug helps reduce the inflammation and scarring that typically lead to kidney failure. This approval expands Travere Therapeutics Inc.’s (NASDAQ:TVTX) reach in the rare kidney disease market, increasing the total addressable US population for FILSPARI (which is already approved for IgA nephropathy) to more than 100,000 patients.

Travere Therapeutics Inc. (NASDAQ:TVTX) is a biopharma company that identifies, develops, and delivers life-changing therapies for people living with rare kidney and metabolic diseases. By focusing on conditions with high unmet needs, such as IgA nephropathy and cystinuria, the company sets new standards of care for patients.

1. Legend Biotech Corporation (NASDAQ:LEGN)

Legend Biotech Corporation (NASDAQ:LEGN) is one of the overlooked growth stocks to buy now. Earlier on March 10, Legend Biotech reported financial results for the full year 2025, headlined by the continued commercial success of its multiple myeloma therapy, CARVYKTI. The treatment generated net trade sales of ~$555 million in Q4 and $1.9 billion for 2025, leading the CARVYKTI franchise to achieve full-year profitability.

This growth was supported by a significant increase in collaboration revenue, which rose to $277.6 million in the final quarter. The company reached a major clinical milestone in 2025, surpassing 10,000 patients treated with CARVYKT across clinical and commercial settings. To support this rising demand, Legend Biotech expanded its Raritan manufacturing facility, making it the largest cell therapy production site in the US with the capacity to treat 10,000 patients annually.

The therapy’s global footprint also grew to 294 sites across 14 markets, with a focus on increasing adoption within the US community and outpatient settings. New data presented at major medical meetings continued to reinforce the durable outcomes associated with using the therapy in earlier lines of treatment. Beyond its flagship product, Legend Biotech Corporation (NASDAQ:LEGN) advanced its early-stage pipeline and research infrastructure. The company opened a new 31,000-square-foot R&D facility in Philadelphia and achieved first-patient dosing for its in vivo pipeline candidates.

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.